Fig. 1From: Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trialBest percentage change from baseline in sum of diameters of target lesions per RECIST v1.1 by a IRC review and b Investigator review (N = 62). IRC = Independent Review Committee, RECIST = Response Evaluation Criteria in Solid Tumors, PD = progressive disease, SD = stable disease, PR = partial response, CR = complete responseBack to article page